Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Expert Opinion on Biological Therapy|November 8, 2008
Oncophage: step to the future for vaccine therapy in melanomaAlessandra di Pietro, Giulio Tosti, Pier F Ferrucci, et al.
Expert Review of Vaccines|October 30, 2009
HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible futureGiulio Tosti, Alessandra di Pietro, Pier Francesco Ferrucci, et al.
Expert Opinion on Biological Therapy|August 2, 2011
The immunological era in melanoma treatment: new challenges for heat shock protein-based vaccine in the advanced diseaseAlessandra di Pietro, Giulio Tosti, Pier Francesco Ferrucci, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 15, 2022
Model-informed drug development supporting the approval of the avelumab flat-dose regimen in patients with advanced renal cell carcinomaJoanna C Masters, Akash Khandelwal, Alessandra di Pietro, et al.
European Journal of Cancer (Oxford, England : 1990)|May 31, 2011
Hormonal and reproductive factors in relation to melanoma in women: current review and meta-analysisSara Gandini, Simona Iodice, Els Koomen, et al.
Cancer Immunology, Immunotherapy : CII|September 20, 2014
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?Luana Calabrò, Giovanni Luca Ceresoli, Alessandra di Pietro, et al.
Oncogene|April 30, 2025
A targeted literature review on the impact of tailored interventions on patient outcomes in oncologyGraham Ferrier, Aleksandra Filipovic, Harpreet Wasan, et al.
Cancer|October 12, 2023
Reliability, validity, and change thresholds of the NCCN/FACT Bladder Symptom Index (NFBlSI-18) in patients with advanced urothelial cancerJohn D Peipert, Jane Chang, Si Li, et al.
The International Journal of Biochemistry & Cell Biology|August 16, 2005
Testicular germ cell tumours: the paradigm of chemo-sensitive solid tumoursAlessandra di Pietro, Elisabeth G E de Vries, Jourik A Gietema, et al.
International Journal of Clinical Oncology|January 1, 2022
Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysisYoshihiko Tomita, Yoshiaki Yamamoto, Norihiko Tsuchiya, et al.
Pageof 4